Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2881669 | 1.00 | LMNA (0.40) | LMNAPDE4BTP53GAAMEN1 | |
| SCHEMBL2876691 | 0.86 | LMNA (0.42) | LMNAPDE4BTP53GAAMEN1 | |
| SCHEMBL2876693 | 0.86 | LMNA (0.42) | LMNAPDE4BTP53GAAMEN1 | |
| SCHEMBL2876399 | 0.83 | MCHR1 (0.42) | LMNATP53GAAMCHR1ALDH1A1 | |
| SCHEMBL2876396 | 0.83 | MCHR1 (0.42) | LMNATP53GAAMCHR1ALDH1A1 | |
| SCHEMBL2883821 | 0.82 | LMNA (0.41) | LMNAGAAMEN1KMT2AKDM4E | |
| SCHEMBL2876596 | 0.68 | MCHR1 (0.53) | MCHR1 | |
| SCHEMBL2876593 | 0.68 | MCHR1 (0.53) | MCHR1 | |
| SCHEMBL2876354 | 0.68 | MCHR1 (0.41) | GAAMCHR1 | |
| SCHEMBL2876352 | 0.68 | MCHR1 (0.41) | GAAMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216758-A1 | Pyridone Compounds | MSD K.K. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-1916239-A1 | PYRIDONE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216758-A1 | Pyridone Compounds | NPY1R, MC5R, MC1R | LMNA 1449/4885PDE4B 2343/4885TP53 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.